We quantified the plasma EV 3R/4R tau ratio and TDP-43 in a large neurodegenerative disease cohort (DESCRIBE cohort) to test the hypothesis that a combination of both markers may distinguish FTLD-tau from FTLD-TDP-43 pathology. The gene discussed is MAPT; the disease is neurodegenerative disease.